AMDL's Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Up
September 20 2007 - 5:00AM
PR Newswire (US)
TUSTIN, Calif., Sept. 20 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi and Jilin, China, through its wholly owned
subsidiary Jade Pharmaceutical Inc. (JPI), is an international
biopharma company that engages in the development, manufacture and
marketing of proprietary pharmaceutical and diagnostic products.
AMDL announced today that JPI has a new product development
strategy focusing on expanded in-house research and development
activities and the in-licensing of new products from 3rd party
pharmaceutical research firms. Frank Zheng, Managing Director of
JPI, stated "Our new product development strategy is expected to
provide at least an additional six new products to the Company's
existing family of strong selling products over the next 36 months.
Additionally, JPI is regularly reviewing various other product
in-licensing opportunities." Gary Dreher, CEO of AMDL, said that
"JPI's outstanding product development strategy is one of the key
engines of growth for the Company." JPI is accelerating its new
product development process beyond the nine new products that have
already been announced. It currently has two products under review
by the SFDA (China State Food and Drug Administration), AMDL's
DR-70(R) cancer diagnostic test kit and Docetaxel Injectables. Both
products are anticipated to be approved for sale in China during
mid-2008. "In order for JPI to manufacture the Docetaxel Injectable
product, they will be required to build a segregated product line
over approximately the next 12 months," Mr. Dreher said. "Docetaxel
is expected to become JPI's best selling product, with estimated
sales of upwards of $10 million per year beginning in mid-2008."
Additionally, four other products are in an R&D phase,
including EO-H, a herbal treatment to improve bone density, TouJin
NiangShi, an herbal liver cancer treatment, and Drotaverrine
Hydrochloric and Diammonium Glycyrrhizinate, which are both
chemotherapy therapeutic products. All four products are currently
expected to gain SFDA approval within the next 24-36 months.
Lastly, AMDL announced that all the matters voted on at the
Company's annual meeting were approved by a majority of the
shareholders. About Jade: Jade has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiary, Jade currently manufactures large volume
injectable fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures 107 generic, over
the counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be
obtained at http://www.amdl.com/ . Forward-Looking Statements: This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: Mr. Paul Knopick, AMDL Investor Relations,
+1-949-707-5365, +1-714-505-4460, voicemail Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024